PRIMARY STUDY

(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB 1 R antagonist/CB 2 R agonist that prevents diabetic nephropathy in mice

Key Findings:  Both (+)-enantiomers of cannabidiol (CBD) in this mouse model show potential therapeutic use in metabolic and immune-related disorders such as Type-1 diabetes and diabetic kidney disease by targeting type 1 and type 2 CB receptors.